A hair loss treatment can make a meaningful difference to confidence and quality of life, but choosing the right one depends on understanding the underlying cause. Hair loss — medically termed alopecia — affects millions of people across the UK, with causes ranging from genetics and hormonal changes to autoimmune conditions and nutritional deficiencies. From over-the-counter minoxidil to prescription finasteride and MHRA-approved JAK inhibitors, the options available in the UK vary considerably in how they work, who they suit, and what safety considerations apply. This guide covers the key treatments, how to access them through the NHS, and when to seek further medical advice.

Understanding Hair Loss: Common Causes and Types

Androgenetic alopecia is the most common cause of hair loss, but other types — including alopecia areata, telogen effluvium, tinea capitis, and scarring alopecias — require different treatments and some need urgent referral.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss, medically known as alopecia, is a common condition affecting both men and women across all age groups. It can range from mild thinning to complete baldness, and understanding the underlying cause is essential before considering a hair loss treatment. The most prevalent form is androgenetic alopecia — commonly called male-pattern or female-pattern hair loss — which is driven by genetic factors and the influence of androgens (male hormones) on hair follicles.

Other recognised types include:

• Alopecia areata — an autoimmune condition causing patchy hair loss

• Telogen effluvium — diffuse shedding often triggered by stress, illness, nutritional deficiency, hormonal changes (such as postpartum hair loss), or certain medicines (including retinoids, anticoagulants, and some thyroid medications); chemotherapy-related hair loss is a related but distinct process

• Tinea capitis — a contagious fungal infection of the scalp, particularly common in children, presenting with patchy hair loss, broken hairs, black dots, scaling, or pustules; it requires prompt antifungal treatment and medical referral to prevent spread and scarring

• Traction alopecia — caused by prolonged tension on the hair from tight hairstyles; modifying hairstyling practices early can prevent progression to scarring

• Trichotillomania — a behavioural condition involving compulsive hair pulling, which warrants psychological support

• Scarring alopecias — rarer conditions where inflammation permanently destroys follicles; suspected scarring alopecia warrants urgent referral to a dermatologist to limit irreversible loss

Identifying the type of hair loss matters because treatments differ significantly between conditions. For example, a treatment effective for androgenetic alopecia may offer little benefit for alopecia areata. Contributing factors such as thyroid dysfunction, iron deficiency anaemia, or nutritional deficiencies should also be excluded, as addressing these underlying causes can itself lead to hair regrowth. A thorough clinical assessment is therefore the appropriate starting point for anyone experiencing noticeable or distressing hair loss.

Useful resources: NICE CKS: Alopecia; NHS: Hair loss; British Association of Dermatologists (BAD) patient information leaflets.

Hair Loss Treatments Available in the UK

Licensed UK options include topical minoxidil (OTC), prescription finasteride for men, and MHRA-approved baricitinib for severe alopecia areata; oral minoxidil and dutasteride are off-label and require specialist supervision.

Several evidence-based options are available in the UK for those seeking a hair loss treatment, ranging from licensed medicines to procedural interventions. The choice of treatment depends on the type and severity of hair loss, the individual's medical history, and personal preference.

Licensed pharmacological treatments include:

• Minoxidil (topical) — available over the counter as a solution or foam in 2% and 5% strengths for both men and women (specific licensed strengths and dosing frequencies vary by formulation and sex; refer to the product's Summary of Product Characteristics or ask a pharmacist). Topical minoxidil is typically purchased over the counter rather than prescribed on the NHS.

• Minoxidil (oral, low-dose) — oral minoxidil tablets are not licensed in the UK specifically for hair loss; their use for this indication is off-label and should only be initiated by a clinician experienced in managing alopecia, with appropriate counselling and monitoring.

• Finasteride (1 mg) — a prescription-only oral tablet licensed for male-pattern hair loss in men; not licensed for use in women of childbearing potential due to the risk of feminisation of a male foetus.

• Dutasteride — sometimes used for androgenetic alopecia in men, but this is an off-label use in the UK (dutasteride is licensed for benign prostatic hyperplasia, not hair loss). It should only be used under specialist supervision with full discussion of the evidence and risks.

For alopecia areata, corticosteroid injections (intralesional triamcinolone) administered by a dermatologist are a well-established option. Topical corticosteroids may also be used. Diphencyprone (DPCP) contact immunotherapy is an unlicensed treatment restricted to secondary care dermatology settings. More recently, JAK inhibitors such as baricitinib (Olumiant) have received MHRA approval for severe alopecia areata in adults, representing a significant advance in treatment options (NICE TA885, 2023).

Non-pharmacological approaches include platelet-rich plasma (PRP) therapy, low-level laser therapy (LLLT), and hair transplant surgery. The evidence base for PRP and LLLT is limited and heterogeneous; these are generally available only privately and are not routinely funded by the NHS.

Useful resources: MHRA/EMC SmPCs for individual products; NICE TA885; BAD guidelines on alopecia areata and contact immunotherapy.

How These Treatments Work and What to Expect

Minoxidil prolongs the hair growth phase, finasteride reduces DHT by inhibiting 5-alpha reductase, and baricitinib blocks JAK signalling driving autoimmune follicle attack; all require consistent, long-term use to maintain benefit.

Understanding the mechanism of action of each hair loss treatment helps set realistic expectations.

Minoxidil's precise mechanism of action in promoting hair growth is not fully understood. It is thought to involve opening of potassium channels (K-ATP channel activation), prolongation of the anagen (growth) phase of the hair cycle, and possible vasodilatory effects around hair follicles. Results are typically gradual — most users notice reduced shedding within 8–12 weeks, with visible regrowth taking up to 6 months. Importantly, any benefit is maintained only with continued use; stopping treatment usually leads to a return of hair loss within months.

Finasteride works by inhibiting the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). DHT is the primary androgen responsible for follicle miniaturisation in androgenetic alopecia. By reducing DHT levels, finasteride slows hair loss and can promote regrowth in many men. A response is typically not apparent for 3–6 months, with maximal benefit often seen at 12–24 months of continuous use. According to the licensed product information, most men who respond experience stabilisation or improvement; individual responses vary and results should not be assumed to be universal.

JAK inhibitors such as baricitinib act by blocking Janus kinase signalling pathways involved in the autoimmune attack on hair follicles in alopecia areata. Clinical trial data (BRAVE-AA1 and BRAVE-AA2, reviewed by NICE in TA885) demonstrated meaningful hair regrowth in a significant proportion of patients with severe disease. As with other hair loss treatments, regrowth achieved with JAK inhibitors may be lost after discontinuation.

Patients should be counselled that:

• No treatment offers a permanent cure for most forms of hair loss

• Consistency is key — irregular use reduces effectiveness

• Initial shedding may temporarily worsen with minoxidil before improvement occurs; this is generally a normal part of the process but should be discussed with a clinician if concerning

• Realistic expectations should be established at the outset, as responses vary between individuals

Useful resources: MHRA/EMC SmPCs for finasteride 1 mg and minoxidil; NICE TA885 evidence summary.

Eligibility, Safety, and MHRA-Approved Options

Finasteride carries MHRA-strengthened warnings (2024) for persistent sexual dysfunction and psychiatric effects; baricitinib carries JAK inhibitor class risks including serious infections, VTE, and malignancy, requiring pre-treatment screening.

When selecting a hair loss treatment, safety and regulatory status are important considerations. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for licensing medicines, and patients are advised to use only appropriately authorised products obtained from legitimate sources.

Minoxidil (topical) is licensed and widely available, but is not suitable for everyone. It should be used with caution in individuals with cardiovascular conditions. Oral minoxidil for hair loss is off-label; important adverse effects include tachycardia, fluid retention (oedema), and, rarely, pericardial effusion. A baseline blood pressure check and cardiovascular assessment are advisable before starting oral minoxidil. Topical and oral minoxidil are generally avoided during pregnancy and breastfeeding; women should seek specialist advice.

Experiencing these side effects? Our pharmacists can help you navigate them →

Finasteride is contraindicated in women who are pregnant or may become pregnant due to the risk of feminisation of a male foetus. Women of childbearing potential should not handle crushed or broken tablets. Men donating blood should be aware that NHS Blood and Transplant advises deferral from blood donation whilst taking finasteride and for one month after stopping.

Importantly, the MHRA has strengthened warnings on finasteride (see MHRA Drug Safety Update, 2024). Reported adverse effects include persistent sexual dysfunction (including decreased libido, erectile dysfunction, and ejaculatory disorders that may continue after stopping the medicine) and psychiatric effects including depression, anxiety, and suicidal ideation. A patient alert card is provided with finasteride; patients should read it carefully. If you experience mood changes, low mood, or sexual side effects whilst taking finasteride, stop the medicine and seek medical advice promptly.

Dutasteride is used off-label for androgenetic alopecia and carries similar risks to finasteride; it should only be used under specialist supervision.

Baricitinib (Olumiant), approved by the MHRA for severe alopecia areata, carries risks consistent with the JAK inhibitor drug class. The MHRA Drug Safety Update (2023) on JAK inhibitors highlights the following class risks: serious and opportunistic infections (including reactivation of tuberculosis and herpes zoster), venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and malignancy. Before starting baricitinib, clinicians should screen for TB and hepatitis, check vaccination status, and assess cardiovascular risk. Ongoing monitoring includes full blood count, liver function tests, and lipid levels. Baricitinib is contraindicated in pregnancy; women of childbearing potential must use effective contraception. NICE guidance (TA885, 2023) recommends baricitinib for adults with severe alopecia areata only when specific clinical criteria are met, and it is subject to a safety monitoring plan.

Key safety considerations include:

• Always purchase licensed medicines from a registered UK pharmacy or prescriber

• Avoid unregulated online sources, which may supply counterfeit or unlicensed products

• Disclose all current medications to your prescriber to avoid interactions

• Women should seek specialist advice before starting any systemic hair loss treatment

• If you experience unexpected side effects — such as chest pain, breathlessness, or palpitations with minoxidil, persistent sexual dysfunction or low mood with finasteride, or signs of infection with baricitinib — stop the medicine and seek medical advice promptly

• Report suspected side effects through the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk)

Useful resources: MHRA Drug Safety Updates (finasteride 2024; JAK inhibitors 2023); MHRA/EMC SmPCs for finasteride 1 mg, minoxidil, and baricitinib; BNF monographs; NICE TA885; NHS Blood and Transplant medication deferral guidance.

Getting a Diagnosis and Treatment Through the NHS

A GP is the appropriate first point of contact for hair loss; they can arrange blood tests to exclude underlying causes and refer to NHS dermatology for complex cases, though many treatments are obtained privately.

The NHS provides pathways for diagnosing and managing hair loss, though access to specialist treatment may vary depending on clinical need and local commissioning decisions. The first step is typically a consultation with a GP (general practitioner), who can take a detailed history, examine the pattern of hair loss, and arrange relevant blood tests.

Common investigations include:

• Full blood count — to exclude anaemia

• Thyroid function tests (TFTs) — to identify hypothyroidism or hyperthyroidism

• Serum ferritin — iron stores are closely linked to hair health

• Hormonal profile — particularly in women with signs of androgen excess (e.g., irregular periods, acne)

If an underlying medical cause is identified, treating it is the priority. Topical minoxidil is typically purchased over the counter rather than prescribed on the NHS; NHS prescribing of minoxidil is uncommon. Finasteride is a prescription-only medicine; NHS availability varies by Integrated Care Board (ICB), and it is often obtained via a private prescription. Referral to an NHS dermatologist is appropriate for complex or uncertain cases, including suspected alopecia areata, suspected scarring alopecia (which warrants urgent referral to prevent permanent loss), suspected tinea capitis (particularly in children, requiring prompt treatment), or where first-line treatments have failed.

Many hair loss treatments — including hair transplant surgery, PRP therapy, and some specialist consultations — are not routinely funded by the NHS. Hair transplant surgery is generally not available on the NHS except for reconstructive or medical indications. Patients seeking these options privately should ensure they consult with appropriately qualified practitioners. Surgeons and doctors should be registered with the General Medical Council (GMC); clinics offering surgical procedures or PRP therapy should be registered with the Care Quality Commission (CQC) — you can verify this on the CQC provider register.

Useful resources: NICE CKS: Alopecia; NHS: Hair loss and hair transplant pages; CQC provider register; BAD guidance on scarring alopecias.

When to Seek Further Medical Advice

Seek prompt GP advice for sudden hair loss, scalp scaling or scarring, hair loss in children, or systemic symptoms; stop finasteride and seek urgent advice if you experience persistent sexual dysfunction, low mood, or suicidal thoughts.

While hair loss is often gradual and non-urgent, certain features warrant prompt medical attention. It is important not to self-diagnose or self-treat without professional guidance, as some causes of hair loss are associated with underlying health conditions that require specific management.

Contact your GP promptly if you notice:

• Sudden or rapid hair loss over a short period

• Patchy hair loss with scalp redness, scaling, broken hairs, or black dots — these features may suggest tinea capitis (a fungal infection), which requires prompt treatment to prevent spread and scarring, particularly in children

• Patchy hair loss with scalp scarring or persistent inflammation — suspected scarring alopecia warrants urgent dermatology referral to prevent irreversible follicle loss

• Hair loss accompanied by fatigue, weight changes, or other systemic symptoms that may suggest thyroid disease or another medical condition

• Hair loss in children, which always warrants medical evaluation

• Psychological distress significantly affecting quality of life — hair loss can have a profound emotional impact, and support including referral to counselling or support groups (such as those offered by Alopecia UK) may be appropriate

If you are already using a hair loss treatment, seek medical advice promptly if you experience:

• Chest pain, breathlessness, palpitations, or ankle swelling with minoxidil

• Persistent sexual dysfunction (decreased libido, erectile dysfunction, ejaculatory disorders), low mood, depression, anxiety, or thoughts of self-harm whilst taking or after stopping finasteride — stop the medicine and seek urgent medical advice; these effects have been reported to persist after discontinuation

• Signs of infection, unusual breathlessness, or leg swelling whilst taking baricitinib or another JAK inhibitor

Be cautious of unregulated clinics or online services offering hair loss treatments without a proper consultation. Check that any clinic offering surgical or PRP treatments is registered with the Care Quality Commission (CQC) and that clinicians are registered with the General Medical Council (GMC).

Report suspected side effects from any medicine through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk — this helps monitor the safety of medicines across the UK.

A thorough assessment by a qualified healthcare professional remains the safest and most effective route to finding an appropriate, evidence-based hair loss treatment tailored to your individual needs.

Useful resources: MHRA Drug Safety Update: Finasteride (2024); NHS: Alopecia areata and tinea capitis pages; Alopecia UK; MHRA Yellow Card scheme.

Frequently Asked Questions